Loading…
In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review
The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, ofte...
Saved in:
Published in: | Molecules (Basel, Switzerland) Switzerland), 2024-07, Vol.29 (13), p.3234 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783 |
container_end_page | |
container_issue | 13 |
container_start_page | 3234 |
container_title | Molecules (Basel, Switzerland) |
container_volume | 29 |
creator | Stagno, Claudio Mancuso, Francesca Ciaglia, Tania Ostacolo, Carmine Piperno, Anna Iraci, Nunzio Micale, Nicola |
description | The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties. |
doi_str_mv | 10.3390/molecules29133234 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_81562414ff3f4ae3b8d16f1636c21cc4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_81562414ff3f4ae3b8d16f1636c21cc4</doaj_id><sourcerecordid>3079857906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783</originalsourceid><addsrcrecordid>eNplkU1vFDEMhiMEoqXwA7igSFy47DaOMx_hVi2lrGiFxMcNKcokHnZWmck2mdmq_75Dt1QITras531l-2XsNYglohanfQzkpkBZakCUqJ6wY1BSLFAo_fSv_oi9yHkrhAQFxXN2hLXWGurimP1cD_xbFzoX-RWNm-gzb2Pi44b4hy67uKd0y2PLP--rpTytlshXGzsMFDK_in4Kdowpv-dnfBX7XaINDbnbE_9K-45uXrJnrQ2ZXj3UE_bj4_n31afF5ZeL9erscuFQinGhoVCFlAKkVw608rpp5lU9YU2Vk0QNlgJAoNW2sVRYqFGCRW91i66q8YStD74-2q3Zpa636dZE25n7QUy_jE1j5wKZGopSKlBti62yhE3toWyhxNJJcE7NXu8OXrsUryfKo-nnP1AIdqA4ZYOi0nVRaVHO6Nt_0G2c0jBfek9JUYOWMwUHyqWYc6L2cUEQ5neM5r8YZ82bB-ep6ck_Kv7khne1GJeL</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3079208192</pqid></control><display><type>article</type><title>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>Stagno, Claudio ; Mancuso, Francesca ; Ciaglia, Tania ; Ostacolo, Carmine ; Piperno, Anna ; Iraci, Nunzio ; Micale, Nicola</creator><creatorcontrib>Stagno, Claudio ; Mancuso, Francesca ; Ciaglia, Tania ; Ostacolo, Carmine ; Piperno, Anna ; Iraci, Nunzio ; Micale, Nicola</creatorcontrib><description>The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties.</description><identifier>ISSN: 1420-3049</identifier><identifier>EISSN: 1420-3049</identifier><identifier>DOI: 10.3390/molecules29133234</identifier><identifier>PMID: 38999185</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; antiepileptic ; Computer Simulation ; Convulsions & seizures ; Crystal structure ; Drug Discovery - methods ; Epilepsy ; Genes ; Hormones ; Humans ; KCNQ ; KCNQ2 Potassium Channel - chemistry ; KCNQ2 Potassium Channel - genetics ; KCNQ2 Potassium Channel - metabolism ; KCNQ3 Potassium Channel - antagonists & inhibitors ; KCNQ3 Potassium Channel - chemistry ; KCNQ3 Potassium Channel - genetics ; KCNQ3 Potassium Channel - metabolism ; Kinases ; Kv7 ; molecular docking ; molecular dynamics ; Mutation ; Neurological disorders ; Physiology ; Potassium ; potassium channel ; Proteins ; Structure-Activity Relationship</subject><ispartof>Molecules (Basel, Switzerland), 2024-07, Vol.29 (13), p.3234</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783</cites><orcidid>0000-0002-6592-4373 ; 0000-0002-1359-8684 ; 0000-0002-9294-6033 ; 0000-0003-3715-8680 ; 0000-0002-7994-8253</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3079208192/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3079208192?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38999185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stagno, Claudio</creatorcontrib><creatorcontrib>Mancuso, Francesca</creatorcontrib><creatorcontrib>Ciaglia, Tania</creatorcontrib><creatorcontrib>Ostacolo, Carmine</creatorcontrib><creatorcontrib>Piperno, Anna</creatorcontrib><creatorcontrib>Iraci, Nunzio</creatorcontrib><creatorcontrib>Micale, Nicola</creatorcontrib><title>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</title><title>Molecules (Basel, Switzerland)</title><addtitle>Molecules</addtitle><description>The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties.</description><subject>Animals</subject><subject>antiepileptic</subject><subject>Computer Simulation</subject><subject>Convulsions & seizures</subject><subject>Crystal structure</subject><subject>Drug Discovery - methods</subject><subject>Epilepsy</subject><subject>Genes</subject><subject>Hormones</subject><subject>Humans</subject><subject>KCNQ</subject><subject>KCNQ2 Potassium Channel - chemistry</subject><subject>KCNQ2 Potassium Channel - genetics</subject><subject>KCNQ2 Potassium Channel - metabolism</subject><subject>KCNQ3 Potassium Channel - antagonists & inhibitors</subject><subject>KCNQ3 Potassium Channel - chemistry</subject><subject>KCNQ3 Potassium Channel - genetics</subject><subject>KCNQ3 Potassium Channel - metabolism</subject><subject>Kinases</subject><subject>Kv7</subject><subject>molecular docking</subject><subject>molecular dynamics</subject><subject>Mutation</subject><subject>Neurological disorders</subject><subject>Physiology</subject><subject>Potassium</subject><subject>potassium channel</subject><subject>Proteins</subject><subject>Structure-Activity Relationship</subject><issn>1420-3049</issn><issn>1420-3049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNplkU1vFDEMhiMEoqXwA7igSFy47DaOMx_hVi2lrGiFxMcNKcokHnZWmck2mdmq_75Dt1QITras531l-2XsNYglohanfQzkpkBZakCUqJ6wY1BSLFAo_fSv_oi9yHkrhAQFxXN2hLXWGurimP1cD_xbFzoX-RWNm-gzb2Pi44b4hy67uKd0y2PLP--rpTytlshXGzsMFDK_in4Kdowpv-dnfBX7XaINDbnbE_9K-45uXrJnrQ2ZXj3UE_bj4_n31afF5ZeL9erscuFQinGhoVCFlAKkVw608rpp5lU9YU2Vk0QNlgJAoNW2sVRYqFGCRW91i66q8YStD74-2q3Zpa636dZE25n7QUy_jE1j5wKZGopSKlBti62yhE3toWyhxNJJcE7NXu8OXrsUryfKo-nnP1AIdqA4ZYOi0nVRaVHO6Nt_0G2c0jBfek9JUYOWMwUHyqWYc6L2cUEQ5neM5r8YZ82bB-ep6ck_Kv7khne1GJeL</recordid><startdate>20240708</startdate><enddate>20240708</enddate><creator>Stagno, Claudio</creator><creator>Mancuso, Francesca</creator><creator>Ciaglia, Tania</creator><creator>Ostacolo, Carmine</creator><creator>Piperno, Anna</creator><creator>Iraci, Nunzio</creator><creator>Micale, Nicola</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6592-4373</orcidid><orcidid>https://orcid.org/0000-0002-1359-8684</orcidid><orcidid>https://orcid.org/0000-0002-9294-6033</orcidid><orcidid>https://orcid.org/0000-0003-3715-8680</orcidid><orcidid>https://orcid.org/0000-0002-7994-8253</orcidid></search><sort><creationdate>20240708</creationdate><title>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</title><author>Stagno, Claudio ; Mancuso, Francesca ; Ciaglia, Tania ; Ostacolo, Carmine ; Piperno, Anna ; Iraci, Nunzio ; Micale, Nicola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>antiepileptic</topic><topic>Computer Simulation</topic><topic>Convulsions & seizures</topic><topic>Crystal structure</topic><topic>Drug Discovery - methods</topic><topic>Epilepsy</topic><topic>Genes</topic><topic>Hormones</topic><topic>Humans</topic><topic>KCNQ</topic><topic>KCNQ2 Potassium Channel - chemistry</topic><topic>KCNQ2 Potassium Channel - genetics</topic><topic>KCNQ2 Potassium Channel - metabolism</topic><topic>KCNQ3 Potassium Channel - antagonists & inhibitors</topic><topic>KCNQ3 Potassium Channel - chemistry</topic><topic>KCNQ3 Potassium Channel - genetics</topic><topic>KCNQ3 Potassium Channel - metabolism</topic><topic>Kinases</topic><topic>Kv7</topic><topic>molecular docking</topic><topic>molecular dynamics</topic><topic>Mutation</topic><topic>Neurological disorders</topic><topic>Physiology</topic><topic>Potassium</topic><topic>potassium channel</topic><topic>Proteins</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stagno, Claudio</creatorcontrib><creatorcontrib>Mancuso, Francesca</creatorcontrib><creatorcontrib>Ciaglia, Tania</creatorcontrib><creatorcontrib>Ostacolo, Carmine</creatorcontrib><creatorcontrib>Piperno, Anna</creatorcontrib><creatorcontrib>Iraci, Nunzio</creatorcontrib><creatorcontrib>Micale, Nicola</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Molecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stagno, Claudio</au><au>Mancuso, Francesca</au><au>Ciaglia, Tania</au><au>Ostacolo, Carmine</au><au>Piperno, Anna</au><au>Iraci, Nunzio</au><au>Micale, Nicola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</atitle><jtitle>Molecules (Basel, Switzerland)</jtitle><addtitle>Molecules</addtitle><date>2024-07-08</date><risdate>2024</risdate><volume>29</volume><issue>13</issue><spage>3234</spage><pages>3234-</pages><issn>1420-3049</issn><eissn>1420-3049</eissn><abstract>The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38999185</pmid><doi>10.3390/molecules29133234</doi><orcidid>https://orcid.org/0000-0002-6592-4373</orcidid><orcidid>https://orcid.org/0000-0002-1359-8684</orcidid><orcidid>https://orcid.org/0000-0002-9294-6033</orcidid><orcidid>https://orcid.org/0000-0003-3715-8680</orcidid><orcidid>https://orcid.org/0000-0002-7994-8253</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1420-3049 |
ispartof | Molecules (Basel, Switzerland), 2024-07, Vol.29 (13), p.3234 |
issn | 1420-3049 1420-3049 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_81562414ff3f4ae3b8d16f1636c21cc4 |
source | PubMed (Medline); Publicly Available Content Database |
subjects | Animals antiepileptic Computer Simulation Convulsions & seizures Crystal structure Drug Discovery - methods Epilepsy Genes Hormones Humans KCNQ KCNQ2 Potassium Channel - chemistry KCNQ2 Potassium Channel - genetics KCNQ2 Potassium Channel - metabolism KCNQ3 Potassium Channel - antagonists & inhibitors KCNQ3 Potassium Channel - chemistry KCNQ3 Potassium Channel - genetics KCNQ3 Potassium Channel - metabolism Kinases Kv7 molecular docking molecular dynamics Mutation Neurological disorders Physiology Potassium potassium channel Proteins Structure-Activity Relationship |
title | In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A42%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Silico%20Methods%20for%20the%20Discovery%20of%20Kv7.2/7.3%20Channels%20Modulators:%20A%20Comprehensive%20Review&rft.jtitle=Molecules%20(Basel,%20Switzerland)&rft.au=Stagno,%20Claudio&rft.date=2024-07-08&rft.volume=29&rft.issue=13&rft.spage=3234&rft.pages=3234-&rft.issn=1420-3049&rft.eissn=1420-3049&rft_id=info:doi/10.3390/molecules29133234&rft_dat=%3Cproquest_doaj_%3E3079857906%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3079208192&rft_id=info:pmid/38999185&rfr_iscdi=true |